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Novel data on electron transport under conditions of vitamin K3
shunt functioning: The inﬂuence of transmembrane potential and
NADH synthesis in intermembrane space
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In our previous reports we demonstrated that presence of oxidized
form of CoQ or another exogenous quinone is crucial for the concrete
path of electron transfer between complexes II and III. Our new results
are devoted to the problem of large respiration rate decrease after
uncoupler addition under conditions of hydrophilic quinone shunt
functioning. This effect has no strict dependence on nature of uncoupler
or hydrophilic quinone. TPP+ uptake and hydrogen peroxide produc-
tion were estimated. The data gives new important information about
electron transfer between hydrophilic quinol and CoQ in P-center of
bc1-complex. In addition, some speculations on a problem of NQO1
supplementation with NAD(P)H in intermembrane space are made.
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Microglial cells play a key role in the pathomechanism of
neurodegenerative disorders. They can enter into metabolically differ-
ent compartments in the CNS. We investigated which compounds can
serve as metabolic fuels for these cells. The oxygen consumption rate
(OCR) and extracellular acidiﬁcation rate (ECAR) were measured
on primary microglial cells and on the BV-2 microglial cell-line with
Seahorse Extracellular Flux Analyzer (Seahorse). ECAR was considered
as a parameter of glycolytic activity. Cells were incubated in Artiﬁcial
Cerebrospinal Fluid (ACSF) supplemented with those substrates, which
are available for the cells in the CSF: glutamine, glucose, lactate, or
pyruvate. All of the substrates applied supported themetabolism of the
cells and none of them inﬂuenced their viability negatively. In the
presence of glutamine the basal rate of respiration was increased.
However in the presence of glucose the OCR was decreased, the ECAR
raised and the addition of a lactate dehydrogenase inhibitor after
glucosewas able to reverse this effect. Adding amitochondrial fatty acid
transporter inhibitor further increased the ECAR in the presence of
glucose. We conclude that microglial cells show high metabolic
plasticity, using a wide range of substrates. From the ECAR results we
claim, that these cells show high glycolytic capacity. Furthermore it was
found that besides glucose glutamine is themost preferred substrate for
microglial cells. Supported by: OTKA (NK 81983), TAMOP (4.2.2./B-09/
1), MTA (MTA TKI 2013) and Hungarian Brain Research Program —
(Grant no. KTIA_13_NAP-A-III/6).
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The mitochondrial aspartate/glutamate carrier isoform 1 (AGC1)
catalyzes a Ca2+-regulated entry of glutamate into mitochondria
in exchange for internal aspartate. In men AGC1 is an essential
component of the malate–aspartate shuttle that transfers NADH
reducing equivalents into mitochondria [1]. Defects in the SLC25A12
gene encoding AGC1 cause AGC1 deﬁciency (OMIM 612949), a novel
neurological disorder that manifests with psychomotor developmen-
tal delay, epileptic seizures and hypomyelination associated with
a reduced N-acetylaspartate (NAA) content in the CNS [2]. Here
we report a novel homozygous SLC25A12 mutation (c.1058G N A,
p.R353Q) identiﬁed in two Indian consanguineous siblings. R353 in
AGC1 is highly conserved in the aspartate/glutamate carrier subfam-
ily (and also in other mitochondrial carrier subfamilies), is located
just below the m(matrix)-gate of the carrier and is thought to
participate in closing and opening the carrier on the matrix side
through an interaction with the highly conserved E383 [3,4]. To
assess the pathogenic potential of the c.1058G N A mutation, wild-
type and R353Q mutant AGC1 were overexpressed in Escherichia coli,
puriﬁed and reconstituted into liposomes. Despite normal insertion
of the mutant protein in the liposomal membrane, R353Q AGC1
caused 85% inhibition of the initial transport rates of [14C]aspartate/
aspartate and [14C]glutamate/aspartate exchanges. Although the
activity is not completely inhibited, the phenotype of the patients
resembles those of the Slc25a12 knockout mice [5] and of the ﬁrst
identiﬁed patient affected by AGC1 deﬁciency, where the mutant
Q590R AGC1 was totally inactive [2]. NAA produced in neurons
is known to undergo transaxonal transfer to oligodendrocytes where
it supplies acetyl groups for the synthesis of myelin lipids. It is
suggested that AGC1 is essential to supply cytosolic aspartate for the
production of NAA and subsequent myelin synthesis.
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